The mechanisms of high EZH2 protein expression in malignant tumors are mainly due to the overexpression of the oncogenes and down-regulation of the suppressors of EZH2. RAS/KARS mutation promotes the expression of EZH2 by activating the MEK-ERK-ELK1 and PI3K-AKT signaling pathways of pancreatic cancer and non-small cell lung cancer23,24. This evidence concerns the gene AKT1 and cancer.